TP53 and endometrial cancer: The four molecular subgroups are: (i) patients with copy number stable, ultra-mutated endometrial cancers characterised by pathogenic variants in the exonuclease domain of DNA polymerase-epsilon (POLE), (ii) patients with hyper-mutated endometrial cancer characterised by microsatellite instability (MSI) due to dysfunctional/deficient mismatch repair genes (dMMR), (iii) an MMR-proficient, low somatic copy number aberration (SCNA) subgroup with a low mutational burden and (iv) a high SCNA subgroup with frequent TP53 mutations.